reported the existence of two LCNEC genomic subtypes with specific transcriptional patterns, which they categorized as type I (NSCLC type) with TP53 and STK11/KEAP1 alterations and type II (SCLC type) with TP53 and RB1 alterations, which is introduced in the upcoming 2021 WHO classification (8). This evidence concerns the gene TP53 and large cell neuroendocrine carcinoma.